Page number 15
8 Investor presentation First three months of 2023 GLP-1 class expansion accelerate 2023 with volume growth across Weekly NBRx scripts (‘000s) 80 US GLP-1 weekly NBRx prescriptions 60 40 20 0 Apr 2021 Ozempic ® Rybelsus ® Victoza ® Apr 2023 NN GLP-1 du NBRx: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo Nordisk; Scripts: Prescriptions; US: United States Note: Class growth calculated as Q1 2023 vs Q1 2022 Source: IQVIA Xponent, NBRx data from week ending 14 Apr 2023. TRx data from week ending 14 Apr 2023. Each data points repre
Page number 16
Novo Nordisk ® es in the US in the first quarter of our portfolio TRx share 60% 40% US GLP-1 TRx market share Class growth ~60% Total GLP-1 scripts (millions) 6 52.9% 5 40.9% 4 29.8% 3 20% 0% Apr 2021 ulaglutide tirzepatide Total monthly GLP-1 scripts 16.3% 2 7.2% 1 4.7% 0 Apr 2023 esents a rolling four-week average
